1111638-10-8

Basic information

• Product Name: 3-Chloro-5H-pyrrolo[2,3-b]pyrazine
• Synonyms: 3-Chloro-5H-pyrrolo[2,3-b]pyrazine;5H-Pyrrolo[2,3-b]pyrazine, 3-chloro-
• CAS NO: 1111638-10-8
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.56906
• Product Categories: Aromatics;Bases & Related Reagents;Heterocycles;Inhibitors;Nucleotides
• Mol File: 1111638-10-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.531
• Storage Temp.: 2-8°C
• PKA: 10?+-.0.50(Predicted)
• CAS DataBase Reference: 3-Chloro-5H-pyrrolo[2,3-b]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-5H-pyrrolo[2,3-b]pyrazine(1111638-10-8)
• EPA Substance Registry System: 3-Chloro-5H-pyrrolo[2,3-b]pyrazine(1111638-10-8)

Safety Data

• Hazardous Substances Data: 1111638-10-8(Hazardous Substances Data)

Usage

Description

3-Chloro-5H-pyrrolo[2,3-b]pyrazine is a chemical compound belonging to the pyrazine family, characterized by its unique molecular structure featuring a chloro group and a pyrrolo ring. It is a versatile intermediate in the synthesis of various complex organic molecules and pharmaceuticals.

Uses

Used in Pharmaceutical Industry:
3-Chloro-5H-pyrrolo[2,3-b]pyrazine is used as a key intermediate in the synthesis of pyrazole compounds, which serve as Raf inhibitors. These Raf inhibitors play a crucial role in the development of targeted cancer therapies, as they help in modulating the Raf/MEK/ERK signaling pathway, which is often dysregulated in various types of cancer.
Used in Chemical Synthesis:
In the field of chemical synthesis, 3-chloro-5H-pyrrolo[2,3-b]pyrazine is utilized as a building block for the creation of more complex molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science. Its unique structure allows for further functionalization and modification, making it a valuable component in the development of novel compounds with diverse properties and applications.

Upstream product

• 1111638-09-5 6-chloro-3-((trimethylsilyl)ethynyl)pyrazin-2-amine 
• 865-47-4 potassium tert-butylate 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 1111638-11-9 3-chloro-5-methyl-5H-pyrrolo[2,3-b]pyrazine 
• 1346172-78-8 2-(3-{5-chloro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine-3-yl}-5H-pyrrolo[2,3-b]pyrazin-5-yl)-N-(2,2,2-trifluoroethyl)acetamide 

Relevant articles and documents

Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors

SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation. SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance. Small-molecule inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site. To broaden our approach to allosteric inhibition of SHP2, we conducted additional hit finding, evaluation, and structure-based scaffold morphing. These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2. We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo. These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

INHIBITORS OF JAK

The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.